Trial intelligence / Profile preview

Pilot screening study of dihydropyrimidine dehydrogenase deficiency before capecitabine in metastatic breast cancer

2008-004136-20Phase 4Completed

Sponsor: Centre Antoine Lacassagne
Start: Oct 2008
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, open-label, single-arm trial of capecitabine in breast cancer, sponsored by Centre Antoine Lacassagne. Primary endpoints: Severe capecitabine-related toxicity during cycles 1 and 2, Diagnostic performance of pretreatment plasma UH2/U ratio and 2 more. Started Oct 2008; status: completed.

Drugs

capecitabine

Conditions

breast cancer

Beyond the preview

Go deeper on 2008-004136-20.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-004136-20.